Features
-
Animal-derived component-free
-
Protein-free/Peptide ingredients-free
-
Chemically Defined
-
DMF Filing in Progress
-
Universality: Support the culture of various CHO cell lines (CHO-K1, CHO_ZN, Horizon, CHO-S, CHO DG44, etc.) in fed-batch, intensified fed-batch and perfusion modes
Advantages
Equivalent or superior performance to global brand products with better price and lead time
4 advanced CMPM (Cone Mixing Pin Milling) powder media production lines to meet different customer demand with high inter-batch consistency (CPK*>1.33)
Safe and compliant: chemically defined formulation minimizes the potential of contamination from animal-derived components and meets relevant compliance and regulatory requirements
EU certified ISO13485:2016 QMS and MDSAP (FDA), all data are traceable
Full documents support for IND application
Strictly selected the "2 domestic+1 imported" raw material supplier model to to ensure a stable and reliable supply chain
*CPK is a standard index to state the capability of one process.  CPK=1.33: the process is capable and meets specification limits. The higher the CPK,the better.
Order Information
Basal Medium
Fed-Batch Cultures
Application | Product Name | Cat. No. | Size | Form | Instructions (PDF) | Inquiries /Sample Applications |
CHO-K1, CHO-ZN, HORIZON, CHO-S, and CHO DG44, etc. | Eden B600S Basal Medium | EXP0109901 | 10 L | Powder | Download | |
EXP0109902 | 200 L | Powder | ||||
Eden B501S Basal Medium | EXP0106001 | 10 L | Powder | Download | ||
EXP0106002 | 200 L | Powder | ||||
Eden B401S Basal Medium | EXP0105901 | 10 L | Powder | Download | ||
EXP0105902 | 100 L | Powder | ||||
EXP0105903 | 200 L | Powder | ||||
Eden B300S Basal Medium | EXP0107901 | 100 L | Powder | Download | ||
EXP0107902 | 200 L | Powder | ||||
EXP0107903 | 10 L | Powder |
Application | Product Name | Cat. No. | Size | Form | Product Instruction (pdf) | Inquiries /Sample application |
CHO-K1, CHO-ZN, HORIZON, CHO-S, and CHO DG44, etc. | Eden F601aS Feed Medium | EXP0112101 | 20 L | Powder | Download | |
EXP0112102 | 10 L | Powder | ||||
EXP0112103 | 1 L | Powder | ||||
Eden F600aS Feed Medium | EXP0108901 | 20 L | Powder | Download | ||
EXP0108902 | 10 L | Powder | ||||
EXP0108903 | 1 L | Powder | ||||
Eden F500aS Feed Medium | EXP0105001 | 1 L | Powder | Download | ||
EXP0105002 | 20 L | Powder | ||||
Eden F400aS Feed Medium | EXP0104801 | 1 L | Powder | Download | ||
EXP0104802 | 20 L | Powder | ||||
Eden F600bS Feed Medium | EXP0108801 | 10 L | Powder | Download | ||
EXP0108802 | 1 L | Powder | ||||
Eden F200bS Feed Medium | EXP0104601 | 1 L | Powder | Download | ||
EXP0104602 | 10 L | Powder | ||||
EXP0104603 | 20 L | Powder | ||||
EXP0104604 | 50 L | Powder |
Performance
Antibodies
In fed-batch culture process, Eden CHO CD media demonstrated significant improvements,including enhanced cell growth rate, maximum viable cell density, and cell viability at harvest. The yield has tripled compared to Brand A, while meeting the customer's requirements on quality attributes, including charge distribution and aggregation. This has effectively reduced he customer's production costs.
In perfusion culture process, Eden CHO CD media outperformed other brands with superior productivity. At VVD=1.0, it achieved 2.2 g/L/day Vp and 19 g/L cumulative product expression in 14 days, 55% higher than Brand B. At VVD=2.0, it reached 3.3 g/L/day Vp and 25 g/L cumulative product expression in 14 days.
Documents
CHO Cell Medium
FAQ
Q1: Does BioEngine provide a Certificate of Analysis (COA) for the products?
Q2: Does the medium contain antibiotics?
Q3:Has the Eden series medium from BioEngine been used in the production of marketed drugs?
Q4: Has the Eden series medium from BioEngine been used in clinical stage antibody/protein production projects?
Q5: What is the turnaround time for customization service of cell culture medium?
Q6: What is the minimum essential media?
Q7: How do I adapt my cells to serum-free medium?
1. Prepare serum-free medium: Make sure you have the appropriate serum-free medium for your cell type. Also, consider adding any necessary supplements or growth factors to the medium to support cell growth.
2. Begin the transition: Start by replacing a small portion of the serum-containing medium with serum-free medium, such as replacing 10% of the medium with serum-free medium. Increase the percentage of serum-free medium every few days until you have completely switched to serum-free medium.
3. Monitor cell growth: During the transition, monitor the cells closely to ensure they are adapting to the serum-free medium. Look for changes in cell morphology or growth rate, which may indicate that the cells are experiencing stress or adapting well to the new medium.
4. Optimize conditions: Once the cells have adapted to the serum-free medium, you may need to optimize the conditions, such as the concentration of supplements or growth factors, to achieve the best growth and viability of the cells.
5. Consider cryopreservation: Once the cells have successfully adapted to serum-free medium, it may be a good idea to cryopreserve a batch of cells to have a backup in case of future problems or contamination.
It is important to note that adapting cells to serum-free medium can be cell-type dependent, and some cells may be more difficult to adapt than others. Therefore, it may be helpful to consult the literature or other researchers who have successfully adapted your cell type to serum-free medium for specific tips or protocols.
Q8: What changes occur when CHO cells transition from adherent culture to suspension culture?
Adherent CHO cells typically grow attached to a surface and require a substrate for attachment and growth. They also tend to have slower growth rates and lower cell densities compared to suspension cultures. In contrast, suspension CHO cells can grow in suspension without substrate attachment and can achieve much higher cell densities.
During the transition process, adherent CHO cells are gradually adapted to grow in suspension culture. This involves gradually reducing the surface area of the culture vessel and increasing the agitation speed to maintain the cells in suspension. Over time, the cells adapt to these new conditions and develop the ability to grow in suspension.
As the cells adapt to suspension culture, several changes occur in their growth characteristics. Suspension CHO cells tend to exhibit faster growth rates, shorter doubling times, and higher maximum cell densities compared to adherent cells. They also often demonstrate increased productivity in terms of recombinant protein production per cell, making them more efficient for protein production. However, suspension cultures require more specialized equipment and processes to maintain the cells in suspension and may be more sensitive to changes in environmental conditions such as pH and dissolved oxygen.
In summary, the transition of CHO cells from adherent to suspension growth involves a gradual adaptation to new culture conditions, resulting in changes in growth characteristics and behavior. Suspension cultures of CHO cells generally exhibit higher growth rates and improved protein production efficiency compared to adherent cultures, but they require specialized equipment and processes to maintain them in suspension.
Q9: What are difference between CAR-T and uCAR-T?
The main difference between CAR-T and UCAR-T is that CAR-T cells are autologous, meaning they are made from the patient's own T cells, while UCAR-T cells are allogeneic, meaning they are made from healthy donors' T cells.
The advantage of UCAR-T cells is that they can be produced in advance and used for multiple patients, which may reduce the cost, time and variability of CAR-T cell therapy. However, UCAR-T cells also face the challenge of avoiding immune rejection and graft-versus-host disease (GVHD), which may require gene editing techniques to remove or modify certain antigens on the donor T cells.
Q10: Why are Vero cells good for growing viruses?
Q11: What medium is used for Sf9 cells?
Q12: What are the causes of cell clumping in suspension cultures, and how to deal with it?
1. Overcrowding of cells: If there are too many cells in the culture, they can start to clump together.
2. Agitation: Excessive shaking or stirring can cause cells to clump together.
3. Cell type: Some cell types are more prone to clumping than others.
4. pH: Changes in pH can affect cell adhesion and cause cells to clump together.
5. Serum concentration: High concentrations of serum can cause cells to clump together.
To deal with clumping of cells in suspension culture, here are some possible solutions:
1. Adjust the cell concentration: If cells are too crowded, reduce the cell concentration to prevent clumping.
2. Adjust the agitation: Reduce the speed of shaking or stirring to minimize cell clumping.
3. Add anti-clumping agents: Some reagents can be added to the medium to prevent cells from clumping together. Common anti-clumping agents include EDTA, citrate, and heparin.
4. Try different media formulations: Some media formulations may be more or less prone to clumping depending on the cell type and culture conditions.
5. Use surface-treated cultureware: Some cultureware is treated to reduce cell adhesion and prevent clumping.
6. Perform a gentle resuspension: If cells have already clumped together, gently resuspend the cells by pipetting or tapping the culture vessel.
By implementing these measures, it is possible to reduce the clumping of cells in suspension culture and maintain a healthy culture. Please contact us if you have any questions of cell culture and our technique support team will give you professional suggestions. "
Q13:What are the advantages of cell-based vaccine production?
1. They do not rely on an adequate supply of chicken eggs to produce each vaccine and can rapidly produce vaccine supplies during an impending pandemic. 2. They offer a faster and more stable production of vaccines compared to embryonic chicken eggs.
3. They may allow for multiple viral vaccines to be produced in the same production platforms and facilities in a more sterile environment. 4. They may avoid some strains that do not grow well on embryonic chicken eggs.
5. They may prevent the spread of transmissible spongiform encephalopathies that may pose a sterility problem with animal serum. 6. They may avoid egg-allergen for people with egg allergies.
7. They may be more effective given that there is a risk that the virus may mutate during its long growth phase in the chicken egg."
Q14: What are the different production platforms for COVID-19 vaccines?
1. mRNA vaccine platform: Examples include the Pfizer-BioNTech vaccine (Comirnaty/BNT162b2) and the Moderna vaccine (Spikevax/mRNA-1273). These vaccines employ messenger RNA (mRNA) to deliver partial genetic information of the virus, triggering the production of the spike protein in human cells and eliciting an immune response.
2. Viral vector vaccine platform: Examples include the AstraZeneca vaccine (Vaxzevria/AZD1222) and the Russian Sputnik V vaccine. These vaccines use modified adenoviruses as vectors to introduce the genetic information of the coronavirus into human cells, leading to the production of viral proteins and induction of an immune response.
3. Protein subunit vaccine platform: Examples include the Novavax vaccine (NVX-CoV2373) and vaccines developed by Guangzhou Institute of Biological Products. These vaccines utilize specific protein components (such as the spike protein) of the virus as antigens to stimulate the immune system to generate an immune response.
4. Inactivated vaccine platform: Examples include the vaccines developed by Sinovac (CoronaVac) and Sinopharm. These vaccines employ inactivated forms of the SARS-CoV-2 virus to induce an immune response when injected into the body.
These are some of the commonly used platforms for COVID-19 vaccine production, and each platform has its unique characteristics and manufacturing processes. Different vaccine manufacturers may employ different technologies and methods to produce vaccines.
BioEngine provides cell culture media for COVID-19 vaccine production, including 293 cell culture media, CHO cell culture media, and Vero cell culture media."
Previous
No Information
Next
No Information
http://www.bioengine-global.com/